The regimen with EMEND targets both key emetic pathways
Only the regimen including EMEND and a 5-HT3 receptor antagonist targets both key pathways involved in CINV17–19
- EMEND, the first and only neurokinin 1 (NK1) receptor antagonist, works via an emetic pathway different from that of 5-HT3 receptor antagonists.
- Substance P plays a role in both acute and delayed nausea and vomiting.19
- In contrast, serotonin release peaks 6 hours after cisplatin chemotherapy and declines to pretreatment levels within 16 hours in the acute phase.27
- The central pathway is activated by substance P and mediated by NK1 receptors highly concentrated in the emetic center of the brain.17
- The peripheral pathway is stimulated by serotonin and mediated by 5-HT3 receptors located primarily in the gut.19
Selected Important Risk Information
EMEND, when administered orally, is a moderate cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitor. Because fosaprepitant is rapidly converted to aprepitant, neither drug should be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions.
Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.
For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
